title: Lipid mediators in organ transplantation: does cyclosporine accelerate coronary atherosclerosis?
authors.forename: M L
authors.initials: ML
authors.lastname: Hess
authors.forename: A
authors.initials: A
authors.lastname: Hastillo
authors.forename: J A
authors.initials: JA
authors.lastname: Thompson
authors.forename: D J
authors.initials: DJ
authors.lastname: Sansonetti
authors.forename: S
authors.initials: S
authors.lastname: Szentpetery
authors.forename: G
authors.initials: G
authors.lastname: Barnhart
authors.forename: R R
authors.initials: RR
authors.lastname: Lower
mesh_terms: D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000008:administration & dosage; D001379:Azathioprine / Q000008:administration & dosage; D002648:Child; D003327:Coronary Disease / Q000209:etiology*; D003524:Cyclosporins / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D016027:Heart Transplantation; D006801:Humans; D006937:Hypercholesterolemia / Q000139:chemically induced / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012306:Risk; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors
chemical_list: D000961:Antilymphocyte Serum; D003524:Cyclosporins; D001379:Azathioprine; D011241:Prednisone